Keywords
Anticoagulation
COVID-19
SARS-CoV-2
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the effects of using Direct Oral Anticoagulants (DOACs) in SARS-CoV-2 infection as anticoagulant therapy in the course of the disease. Methods: This is an integrative literature review study, in which the following databases were used: Medical Literature Analysis and Retrieval System Online (MEDLINE/PubMed), Latin American and Caribbean Literature in Health Sciences (LILACS ), Spanish Bibliographic Index in Health Sciences (IBECS) and Scientific Electronic Library Online (SciELO), with the following descriptors, in health sciences (DEcS): ”(Covid OR long Covid OR post Covid OR Post-Acute COVID-19 Syndrome) AND Factor Xa Inhibitors”. It was used as a guiding question: can DOACs be used safely in COVID-19 infection as anticoagulant therapy? Results: The final sample consisted of 15 articles that showed adverse effects and optimistic results regarding the use of DOACs in COVID-19. Final considerations: DOACs seem advantageous on an outpatient basis, but doubts remain regarding possible undesirable drug interactions.
References
ALKHAMEYS S, BARRETT R. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021). Curr Med Res Opin. 2022;38(7):1081-1092.
ALHAWITI NM, et al. Clinical Outcomes of Anticoagulant Therapy in COVID-19 Patients with Pre-Existing Cardiovascular Diseases: A Systematic Review. Infect Drug Resist. 2023;16:3767-3775.
ALY R, et al. The use of direct acting oral anticoagulants in patients with COVID-19 infection. J Community Hosp Intern Med Perspect. 2021;11(2):184-186.
ASLAN B, et al. The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19. Int J Clin Pract. 2021;75(9):e14467.
AVEZUM A, et al. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE–COALITION VIII randomised clinical trial. EClinicalMedicine, v. 60, 2023.
BISTROVIC P, et al. Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - A retrospective cohort study on 5392 patients from a tertiary centre. Int J Cardiol. 2023;372:144-149.
BUENEN AG, et al. Prior use of anticoagulation is associated with a better survival in COVID-19. J Thromb Thrombolysis. 2021;52(4):1207-1211.
CONNORS JM, LEVY JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.
FLAM B, et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411-419.
GATTO MC, et al. Efficacy and Safety of Anticoagulant Therapy in COVID-19-Related Pulmonary Embolism with Different Extension. Biomedicines. 2023;11(5):1282.
HELMS J, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.
HESS R, et al. Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19. Ann Pharmacother. 2023;57(8):918-924.
HOZAYEN SM, et al. Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine. 2021;41:101139.
KRAVCHENKO OV, et al. Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C). BMJ Open. 2022;12(12):e066846.
MOTLOCH LJ, et al. Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. Front Cardiovasc Med. 2022;9:916156.
PANAHI L, et al. Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina (Kaunas). 2021;57(2):110.
POPA P, et al. Mortality Rate in Upper Gastrointestinal Bleeding Associated with Anti-Thrombotic Therapy Before and During Covid-19 Pandemic. J Multidiscip Healthc. 2022;15:2679-2692.
POTERE N, et al. Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone. J Thromb Thrombolysis. 2022;53(2):346-351.
RIVERA-CARAVACA JM, et al. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. Int J Clin Pract. 2022;2022:7325060.
RIVERA-CARAVACA JM, et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021;205:1-7.
RIVERA-CARAVACA JM, et al. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. Cardiovasc Diabetol. 2021;20(1):176.
ROGULJIĆ H, et al. The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?. Croat Med J. 2022;63(3):287-294.
SCHUTGENS RE. DOAC in COVID-19: Yes or No?. Hemasphere. 2020;5(1):e526.
SMYTHE MA, et al. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?. Ann Pharmacother. 2022;56(3):319-329.
TANG N, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
TESTA S, et al. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15(5):751-753.